Clinical Trial: Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients

U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06814600) titled 'Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients' on Jan. 30.

Brief Summary: Non-alcoholic Fatty Liver Disease (NAFLD) refers to a spectrum of disease characterized by the presence of more than 5% of steatosis in hepatocytes of individuals who consume little or no alcohol. It ranges from simple steatosis without evidence of inflammation, to the association of steatosis and inflammation with cellular necrosis, the so-called non-alcoholic steatohepatitis (NASH). NAFLD has become increasingly common in developed countries affecting up to 38% of the population. It is mostly but not exclusively associ...